{'fraction_non_alphanumeric': 0.024229074889867842, 'fraction_numerical': 0.022026431718061675, 'mean_word_length': 5.584541062801932, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
FAM83H‐AS1 is associated with clinical progression and modulates cell proliferation, migration, and invasion in bladder cancer

FAM83H‐AS1, also known as oncogenic long noncoding RNA (lncRNA)‐3, is a novel lncRNA that has been suggested to be dysregulated in a variety of human cancers. However, the expression status and function of FAM83H‐AS1 in bladder cancer are still unknown. The object of our study is to explore the clinical value of FAM83H‐AS1 in patients with bladder cancer and the biological function of FAM83H‐AS1 in bladder cancer cells. In our results, the expression of FAM83H‐AS1 was obviously elevated in bladder cancer tissue samples and bladder cancer cell lines compared with adjacent normal tissue samples and normal bladder epithelial cell lines, respectively. In addition, high expression of FAM83H‐AS1 was associated with advanced clinical stage and the presence of muscularis invasion and served as an independent poor prognostic factor for overall survival in patients with bladder cancer. The loss‐of‐function study showed that silencing FAM83H‐AS1 expression suppressed cell proliferation, migration, and invasion and induced cycle arrest at G0/G1 phase. In conclusion, FAM83H‐AS1 is involved in the progression of bladder cancer and serves as a prognostic biomarker and potential therapeutic target for patients with bladder cancer.